Cargando…

Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma

Because there are few studies regarding the clinical impact of circulating EBV-DNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBV-DNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yu Ri, Kim, Soo-Jeong, Cheong, June-Won, Chung, Haerim, Jang, Ji Eun, Kim, Yundeok, Yang, Woo-Ick, Min, Yoo Hong, Kim, Jin Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696183/
https://www.ncbi.nlm.nih.gov/pubmed/29190917
http://dx.doi.org/10.18632/oncotarget.21251
_version_ 1783280394653663232
author Kim, Yu Ri
Kim, Soo-Jeong
Cheong, June-Won
Chung, Haerim
Jang, Ji Eun
Kim, Yundeok
Yang, Woo-Ick
Min, Yoo Hong
Kim, Jin Seok
author_facet Kim, Yu Ri
Kim, Soo-Jeong
Cheong, June-Won
Chung, Haerim
Jang, Ji Eun
Kim, Yundeok
Yang, Woo-Ick
Min, Yoo Hong
Kim, Jin Seok
author_sort Kim, Yu Ri
collection PubMed
description Because there are few studies regarding the clinical impact of circulating EBV-DNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBV-DNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7%) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBV-DNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients.
format Online
Article
Text
id pubmed-5696183
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56961832017-11-29 Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma Kim, Yu Ri Kim, Soo-Jeong Cheong, June-Won Chung, Haerim Jang, Ji Eun Kim, Yundeok Yang, Woo-Ick Min, Yoo Hong Kim, Jin Seok Oncotarget Research Paper Because there are few studies regarding the clinical impact of circulating EBV-DNA in peripheral T-cell lymphomas (PTCLs), we tried to evaluate the role of EBV-DNA in whole blood as a prognostic factor for PTCL. We retrospectively reviewed 110 PTCL patients with median age of 63 (20-94) years. Forty-seven patients (42.7%) showed positive results for EBV-DNA, and these patients also had stage III/IV disease, elevated lactic dehydrogenase, and low albumin level (P = 0.007, P = 0.004, P = 0.002, respectively). The 5-year overall survival (OS) and progression free survival (PFS) were 21.0% and 18.0%. Univariable analysis showed that positive EBV-DNA was related with inferior OS and PFS (P = 0.015 and P < 0.001, respectively). Multivariable analysis showed that poor performance status, extranodal involvement more than one site and positive EBV-DNA results were related with OS and PFS (P < 0.001, P < 0.001, P = 0.007 and P = 0.001, P = 0.002, P < 0.001, respectively). Using these three variables, we made a new prognostic model which classified patients on risk as follows: low, no adverse factors; intermediate, 1 factor; or high, 2-3 factors. The new prognostic model could stratify the three groups for OS and PFS better than either international prognostic index or prognostic index of PTCL-u, and showed statistical significance in PTCL, not otherwise specified. This study suggests that whole blood EBV-DNA is related with aggressive clinical characteristics and inferior survival. The new prognostic model, which incorporates EBV-DNA, could better stratify PTCL patients. Impact Journals LLC 2017-09-23 /pmc/articles/PMC5696183/ /pubmed/29190917 http://dx.doi.org/10.18632/oncotarget.21251 Text en Copyright: © 2017 Kim et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Kim, Yu Ri
Kim, Soo-Jeong
Cheong, June-Won
Chung, Haerim
Jang, Ji Eun
Kim, Yundeok
Yang, Woo-Ick
Min, Yoo Hong
Kim, Jin Seok
Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
title Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
title_full Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
title_fullStr Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
title_full_unstemmed Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
title_short Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma
title_sort pretreatment epstein-barr virus dna in whole blood is a prognostic marker in peripheral t-cell lymphoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696183/
https://www.ncbi.nlm.nih.gov/pubmed/29190917
http://dx.doi.org/10.18632/oncotarget.21251
work_keys_str_mv AT kimyuri pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT kimsoojeong pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT cheongjunewon pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT chunghaerim pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT jangjieun pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT kimyundeok pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT yangwooick pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT minyoohong pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma
AT kimjinseok pretreatmentepsteinbarrvirusdnainwholebloodisaprognosticmarkerinperipheraltcelllymphoma